ELOCOM CREAM

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

MOMETASONE FUROATE

Доступно од:

ORGANON CANADA INC.

АТЦ код:

D07AC13

INN (Међународно име):

MOMETASONE

Дозирање:

0.1%

Фармацеутски облик:

CREAM

Састав:

MOMETASONE FUROATE 0.1%

Пут администрације:

TOPICAL

Јединице у пакету:

15G/50G

Тип рецептора:

Prescription

Терапеутска област:

ANTI-INFLAMMATORY AGENTS

Резиме производа:

Active ingredient group (AIG) number: 0121732001; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2011-03-21

Карактеристике производа

_ELOCOM_
®
_(mometasone furoate) _
_Page 1 of 32 _
PRODUCT MONOGRAPH
ELOCOM
®
Mometasone Furoate Cream, BP
Mometasone Furoate Ointment, Organon Standard
Mometasone Furoate Lotion
0.1%
Topical Corticosteroid Therapy
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, Quebec
H9H 4M7
www.organon.ca
Date of Preparation:
March 2, 2011
Date of Revision:
April 30, 2021
Control #: 250395
_ELOCOM_
®
_(mometasone furoate) _
_Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
CLINICAL TRIALS
..........................................